

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2819993

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.	03/31/2014
RECEIVING PARTY DATA		
Name:	SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.	
Street Address:	2438 MIYANOURA-CHO	
Internal Address:	KAGOSHIMA-SHI	
City:	KAGOSHIMA	
State/Country:	JAPAN	
Postal Code:	891-1394	
Name:	THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE	
Street Address:	1-6-1 OKUBO, KITA-KU	
Internal Address:	KUMAMOTO-SHI	
City:	KUMAMOTO	
State/Country:	JAPAN	
Postal Code:	860-8568	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	13640623	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(202) 973-8800	
Email:	cedwards@wsgr.com	
Correspondent Name:	WILSON SONSINI GOODRICH & ROSATI, PC	
Address Line 1:	650 PAGE MILL ROAD	
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1050	
ATTORNEY DOCKET NUMBER:	37974-720.831	
NAME OF SUBMITTER:	SHAN LIU	
SIGNATURE:	/ SHAN LIU /	
DATE SIGNED:	04/18/2014	

PATENT

Total Attachments: 1

source=37974_720_831_Assignment_Corporate#page1.tif

CORPORATE TO CORPORATE ASSIGNMENT

Docket Number 37974-720.831

WHEREAS, Shin Nippon Biomedical Laboratories, Ltd. (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the Application(s), and in and to all embodiments of the inventions, heretofore conceived, made or discovered (collectively hereinafter referred to as "Inventions") entitled:

METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY

- ☐ for which a United States patent application is executed on even date herewith;
☒ for which application serial number 13/640,623 was filed on October 11, 2012 in the United States Patent and Trademark Office;
☐ for which application serial number _____ was filed on _____ in the U.S. Receiving Office of the Patent Cooperation Treaty;
☐ for which application serial number _____ was filed on _____ in the _____ Patent Office; and/or
☐ for which an application was filed upon which a United States Patent issued on _____, as U.S. Patent No. _____ (hereinafter "Application(s)"). The term "Application(s)" also includes all patent applications that share or claim priority to or from the above application(s).

WHEREAS, The Chemo-Sero-Therapeutic Research Institute, having a place of business at 1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto, 860-8568, Japan, (hereinafter "Assignee"), is desirous of acquiring 50% of right, title and interest in and to only the subject matter of claims 24-42 of U.S. Application No. 13/640,623 as pending on October 11, 2012.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee 50% of right, title and interest (a) in and to only the subject matter of claims 24-42 of U.S. Application Serial No. 13/640,623 as pending on October 11, 2012.
2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States.
3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.
4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
5. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

Date: 31 Mar. 2014

ASSIGNOR

By:

Name: Mr. Hideyuki Hironaka
 Title: Executive Officer, Senior Director of Translational Research Division

RECEIVED AND AGREED TO BY ASSIGNEE:

Date: 28 Mar. 2014

By:

Name: Mr. Seiji Miyamoto
 Title: Director General